Source: Shutterstock/SUWIT NGAOKAEW

Promising research

First steps towards a new, targeted lung cancer treatment

Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

They found lung squamous cell carcinoma (LUSC) cells contained high amounts of a protein called BCL11A. The study showed that manipulating the gene responsible for the protein stopped the development of LUSC in a mouse model of the disease. The study also revealed a signalling pathway that BCL11A was involved in, and found a potential druggable target, called SETD8. Targeting this molecule both genetically and with early forms of drugs, selectively targeted LUSC cancer cells growing in the lab, and in LUSC cells transplanted into mice.

How LUSC develops is a bit of puzzle – until now our molecular understanding of this process was limited

Kyren Lazarus

These early discoveries have led to further funding being granted by Cancer Research UK to facilitate the development of a drug to target the protein, which could one day lead to a new treatment option for some people with lung cancer.

Dr Kyren Lazarus, study author from the University of Cambridge, said: “How LUSC develops is a bit of puzzle – until now our molecular understanding of this process was limited. Our research has revealed a major piece of this puzzle, which we are now actively trying to make new drugs against.”

Over the last 40 years, lung cancer survival has remained stubbornly low, particularly when compared to overall cancer survival which has more than doubled. One of the reasons for this is the lack of targeted treatments for lung cancer, and currently just 5 in 100 people survive their disease for 10 or more years.

Dr Walid Khaled, lead author from the University of Cambridge, said: “Developing targeted treatments is a real opportunity for improving the outlook for patients. With this new drug discovery grant from Cancer Research UK we are working to develop small molecules to specifically block BCL11A in LUSC cells. We are aiming to disrupt critical interactions that BCL11A has with other proteins and are working closely with our colleagues at the Department of Biochemistry in Cambridge and CRUK Beatson Institute Drug Discovery Unit to achieve this.”

Professor Karen Vousden, Cancer Research UK’s chief scientist, said: “Identifying potentially druggable targets is an early yet crucial stage in the journey towards precision medicine. While there is much to be done before this work could be translated into patient benefit, it’s a fundamental step towards that goal and we look forward to seeing how this discovery progresses along the research pipeline.”


Source: Cancer Research UK

23.08.2018

Read all latest stories

Related articles

Medical nanoparticles

Local treatment of lung cancer

Nanoparticles are extremely small particles that can be modified for a variety of uses in the medical field. For example, nanoparticles can be engineered to be able to transport medicines…

Shared standards critical in lung cancer screening

Findings from the landmark National Lung screening Trial (NLST) continue to make waves in the United States, and increasingly around the world. The principal investigator for the component of the…

Study shows relation between LKB1 gene and lung cancer

Lung cancer has a high mortality: Despite prevention programms each year 1.3 million people die due to malignant mutation of lung cells. It's the most common cause of cancer-related death in men,…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH